Lasokun (Ranolazine)

Ranolazine works by selectively inhibiting the late inward sodium current in cardiac cells. This reduces intracellular sodium and secondary calcium overload, which improves myocardial relaxation and makes the heart muscle use oxygen more efficiently during periods of limited blood supply, thereby reducing angina symptoms.

The dosage of Lasokun is determined by the prescribing physician based on the individual’s clinical condition, renal function, and response to therapy. The prescriber will select the appropriate strength and titration schedule, and patients should follow the prescribed regimen exactly as instructed.

The safety of ranolazine in pregnancy and lactation has not been established. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare professional.

To request Lasokun, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Unlike beta‑blockers or calcium‑channel blockers, ranolazine does not significantly affect heart rate or blood pressure. Its unique mechanism of reducing intracellular sodium makes it a useful adjunct for patients who remain symptomatic despite standard therapy, offering an alternative when conventional agents are insufficient or not tolerated.

Lasokun tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the medication out of reach of children and do not use it after the expiry date printed on the packaging.

Lasokun is taken orally, usually with or without food, as directed by the prescribing clinician. The tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed by a healthcare provider.

The most serious adverse effects include QT interval prolongation, which can lead to potentially life‑threatening arrhythmias, severe allergic reactions such as Stevens‑Johnson syndrome, and hepatic injury. Patients should be monitored for cardiac rhythm changes and liver function abnormalities during therapy.

Lasokun is contraindicated in patients with known prolonged QT interval, those taking other QT‑prolonging medications, and individuals with severe hepatic impairment. It should also be avoided in patients with a history of serious hypersensitivity to ranolazine or any of the tablet’s excipients.